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A B S T R A C T
The efficient and reproducible production of nanoparticles using bulk nanoprecipitation methods is still chal-
lenging because of low batch to batch reproducibility. Here, we optimize a bulk nanoprecipitation method using
design of experiments and translate to a microfluidic device to formulate surface-modified poly-lactic-co-glycolic
(PLGA) nanoparticles. Cell-penetrating peptides (CPPs) with a short, long linear or branched architecture were
used for the surface modification of PLGA nanoparticles. The microfluidics method was more time efficient than
the bulk nanoprecipitation method and allowed the formulation of uniform PLGA nanoparticles with a size of
150 nm, a polydispersity index below 0.150 and with better reproducibility in comparison to the bulk nano-
precipitation method. After surface modification the size of CPP-tagged PLGA nanoparticles increased to
160–180 nm and the surface charge of the CPP-tagged PLGA nanoparticles varied between−24mV and +3mV,
depending on the architecture and concentration of the conjugated CPP. Covalent attachment of CPPs to the
PLGA polymer was confirmed with FTIR by identifying the formation of an amide bond. The conjugation effi-
ciency of CPPs to the polymeric PLGA nanoparticles was between 32 and 80%. The development and design of
reproducible nanoformulations with tuneable surface properties is crucial to understand interactions at the
nano-bio interface.
1. Introduction
Efficient production of nanoparticles for drug delivery applications
is increasingly important to ensure that the benefits of these delivery
systems are translated from ‘bench to bedside’. Nanoprecipitation is one
of the most commonly used techniques for the preparation of polymeric
nanoparticles and is suitable to encapsulate proteins, hydrophobic and
poorly water soluble drugs (Banik et al., 2016; Danhier et al., 2012;
Jung et al., 2000). Polymeric nanoparticles are usually prepared using a
bulk beaker method with volumes up to 50mL (Fessi et al., 1989). The
nanoprecipitation method involves mixing of an organic, water-mis-
cible solvent like acetone, ethanol or acetonitrile with an aqueous so-
lution (Masood, 2016; Yadav and Sawant, 2010). Surfactants like the
non-ionic polyvinyl alcohol (PVA) are added to the aqueous phase to
act as a stabilizer and to reduce the interfacial tension between the
organic and aqueous phase (Tefas et al., 2015). Mixing the organic and
aqueous phases leads to a reduction in polymer solubility and nano-
particles assemble due to nucleation and subsequent growth of the
polymer (Karnik et al., 2008). Nanoprecipitation is characterized by the
production of nanoparticles with a narrow size distribution (poly-
dispersity index below 0.2) and the potential to scale up the technique
to an industrial scale (Danaei et al., 2018; Galindo-Rodríguez et al.,
2005; Masood, 2016). The main drawback, however of bulk prepara-
tion methods is the variation in nanoparticle size from batch to batch
due to the limited control over fluid dynamics during nanoparticle
formation and aggregation of the polymeric nanoparticles (Donno et al.,
2017; Jara et al., 2018). This variability in nanoparticle size can lead to
variability in uptake following administration and therefore, undesir-
able inconsistencies in therapeutic effect.
A recent advance in the production of nanoparticles that offers su-
perior nanoparticle size uniformity is microfluidics (Valencia et al.,
2012). Liquid reagents are introduced into a microfluidics chip at pre-
specified total flow rates and flow rate ratios, which are expressed as
the combined flow rate of the liquid reagents and the ratio between the
aqueous and organic phase, respectively. Using microfluidics, nanoliter
amounts of liquid reagents are rapidly mixed in a microchannel in a
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highly controlled way (Garg et al., 2016). In order to increase the
mixing efficiency, passive mixers are incorporated into the micro-
channel (Capretto et al., 2013). The staggered herringbone mixer
(SHM) is a common passive mixer and is described as an in-floor groove
in the microchannel with the shape of an asymmetric herringbone
(Belliveau et al., 2012). Using the SHM configuration, mixing is induced
by chaotic advection and contributes to an increased mixing efficiency
and reduced mixing times (Belliveau et al., 2012; Stroock et al., 2002).
The biodegradable and biocompatible polymer poly (lactic-co-gly-
colic acid) (PLGA) is the most commonly used polymer for the for-
mulation of nanomedicines (Danhier et al., 2012). The size and poly-
dispersity of PLGA nanoparticles can be optimized using microfluidic
devices by using a high total flow rate of the two miscible solvents and a
high flow rate ratio between the aqueous and organic phase, while
using polymers with a low molecular weight to produce monodisperse
nanoparticles below 180 nm in size (Chiesa et al., 2018; Donno et al.,
2017; Morikawa et al., 2018).
Cell-penetrating peptides (CPPs) show great potential to facilitate
enhanced cell uptake of therapeutic compounds (Nel et al., 2009;
Vasconcelos et al., 2015). The translocation ability applies to the CPP
on its own and also for conjugates of the CPPs with different cargos like
nanoparticles and macromolecules such as peptides, proteins and DNA
oligomers (Feiner-Gracia et al., 2018; Kristensen et al., 2015; Trehin
et al., 2004). The internalisation of CPPs is proposed to occur via direct
translocation or endocytic pathways (Birch et al., 2018) and is influ-
enced by the structure and concentration of the CPP, the cargo and the
cell type (Cardoso et al., 2012; Hoyer et al., 2012). Several strategies for
the application of CPPs have been described in the literature and in-
clude a co-administration of CPPs with the drug, formation of a cova-
lent bond between CPP and drug, as well as a surface modification of
nanoparticles with CPPs (Liu et al., 2013). Surface modification of
polymeric nanoparticles to enhance delivery of macromolecules is a
prudent approach that does not alter the bioactivity of the encapsulated
macromolecule (Jain and Jain, 2015; Liu et al., 2013).
We have exploited our discovery that histidine co-polymerizes with
polymeric nanoparticles to covalently attach CPPs to the nanoparticle
wall (Chiu et al., 2015; Kafka et al., 2009). Our previous work has
shown that a short peptide, RRH (arginine-arginine-histidine), in-
creased the cellular uptake of RRH-modified poly(ethyl-cyanoacrylate)
(PECA) nanoparticles in Caco-2 cells by 30% in comparison to un-
modified PECA nanoparticles (Chiu et al., 2015). Other studies have
shown that dendrimers based on the CPP Tat (47–57) with a multi-
branched topology containing arginine-rich branches showed higher
uptake with a 10–15 times higher florescence intensity in HeLa cells in
comparison to the linear Tat (Eggimann et al., 2014). To the best of our
knowledge branched CPPs have not yet been conjugated to polymeric
nanoparticles to enhance their cellular uptake.
The aim of this study was to optimize a bulk nanoprecipitation
method for the formulation of PLGA nanoparticles using a design of
experiments approach. The bulk nanoprecipitation method was then
compared with a microfluidics method to evaluate the uniformity of the
formulated PLGA nanoparticles. Further, PLGA nanoparticles prepared
with the microfluidics method were surface-modified with CPPs of
different architectures (Fig. 1) to alter their physicochemical properties.
The modified nanoparticles were characterized and can potentially be
used as a drug delivery system to enhance uptake after oral adminis-
tration.
2. Materials and methods
2.1. Materials
Poly(DL-lactide-co-glycolide) (PLGA) 50:50, ester terminated, MW
15,980 Da, was supplied by Durect Lactel (Cupertino, USA).
Acetonitrile (ACN) (HPLC grade) was supplied by Merck (Darmstadt,
Germany). Mowiol® 4-88 (polyvinyl alcohol, PVA, MW 31,000), 2-[4-
(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES)
(purity > 99.5%), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide
hydrochloride (EDC) (purity> 98%), trifluoroacetic acid (TFA, HPLC
grade, purity> 99%) and GRKKRRQK(RRH)K(RRH)K(RRH) (bTAT,
custom synthesized, MW 2661.2 Da, purity> 95%) were purchased
from Sigma–Aldrich (St. Louis, USA). Snake Skin™ dialysis tubing
(10 kDa MWCO) and sulfo-N-hydroxysulfosuccinimide (sulfo-NHS)
were purchased from Thermo Fisher Scientific Australia Pty (Scoresby,
Australia). The peptides RRH (MW 467.3 Da, purity> 98%) and
GRKKRRQRRR (TAT (48–57), MW 1396.7 Da, purity> 98%) were
custom synthesized by GLS (Shanghai, China) and used as supplied.
Distilled, ultra-pure water was produced using a Milli-Q water Millipore
Purification System™ (Billerica, MA, USA).
In this work, CPPs with three different architectures were designed
for conjugation to PLGA nanoparticles to be able to investigate how the
architecture of the CPPs influences cell uptake (Fig. 1). The short RRH
was chosen from our previous work (Chiu et al., 2015), the long linear
CPP was the widely investigated TAT peptide and for the third, we
designed a branched TAT (bTAT), which has a modified TAT backbone
with three RRH side branches (Fig. 1).
2.2. Methods
2.2.1. Design of experiments to optimize preparation of PLGA nanoparticles
using a bulk nanoprecipitation method
A design of experiments study was used to identify the optimal
concentration of PLGA, PVA and solvent evaporation time for the ap-
plied bulk nanoprecipitation method. MODDE GO 12 software
(Umetrics, Umeå, Sweden) was used for the design and analysis of the
experiments. After definition of the input parameters, a full factorial (2-
levels) design with a center point for objective screening was used to
define parameters for the individual experiments (Table 1). The se-
lected response parameters for the PLGA nanoparticles were size and
polydispersity index (PDI). For the validation of how well the model fits
the data (R2) and to validate the ability to predict new data (Q2),
analysis of variance (ANOVA) was performed. Further statistical testing
included, testing the regression model for significance to obtain a
probability value (p) and a lack of fit test to estimate the error of the
model.
Fig. 1. Illustration of the architecture of the short (RRH), the long linear (TAT)
and the branched CPP (bTAT: modified TAT backbone and three RRH bran-
ches). Amino acid single letter code is used (R= arginine, H=histidine,
G= glycine, K= lysine, Q=glutamine).
Table 1
Input parameters for the design of experiments study to optimize the for-
mulation of PLGA nanoparticles using a bulk nanoprecipitation method.
Parameters Level
−1 0 1
PLGA concentration (mg/mL) 2 13.5 25
PVA concentration (% w/v) 0.5 2.75 5
Stirring time (h) 0.5 2.25 4
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2.2.2. Bulk nanoprecipitation method for preparation of PLGA
nanoparticles
PLGA nanoparticles were prepared using a bulk nanoprecipitation
method based on the description by Fessi et al. (1989). Briefly, an or-
ganic PLGA solution (10mg/mL in ACN) was added dropwise to a
beaker containing 10mL PVA (2% w/v in ultra-pure water) and the
solvent was evaporated during magnetic stirring for 2 h and 15min.
The resulting PLGA nanoparticles were washed twice with ultra-pure
water by centrifugation at 17,900g for 10min (Eppendorf 5417 C
centrifuge) at room temperature and stored as suspension in ultra-pure
water at 4 °C until required with a maximum storage time of 7 days.
2.2.3. Microfluidics method for preparation of PLGA nanoparticles
PLGA nanoparticles were prepared using the NanoAssemblr®
Benchtop Device (Precision NanoSystems, Vancouver, Canada). The
aqueous PVA (2% w/v) solution was mixed with the organic PLGA
solution (10mg/mL in ACN) at a flow rate ratio (aqueous:organic) of
6:1 and a total flow rate of 10mL/min (Streck et al., 2019). PLGA na-
noparticles were dialyzed overnight against ultra-pure water at room
temperature using Snake Skin™ dialysis tubing (10 kDa MWCO) and
stored as suspension in ultra-pure water at 4 °C until required with a
maximum storage time of 7 days.
2.2.4. Preparation of CPP-tagged PLGA nanoparticles
Prior to surface-modification, both types of PLGA nanoparticle
suspensions produced with the bulk nanoprecipitation and the micro-
fluidics method as described in Sections 2.2.2 and 2.2.3 were dialyzed
overnight against ultra-pure water at room temperature using Snake
Skin™ dialysis tubing (10 kDa MWCO).
A zero-length crosslinking reaction for the conjugation of CPPs to
the surface of PLGA nanoparticles was adapted from Egusquiaguirre
et al. (2015) with some modifications. Briefly, 500 µL of the PLGA
nanoparticle suspension was diluted with HEPES buffer (0.025M, pH
6.4) to 1.5 mL and the nanoparticle suspension was gently stirred while
adding 250 µL EDC (1.5mM in ultra-pure water) and 250 µL sulfo-NHS
(2mM in ultra-pure water). The stirring continued for 30min at room
temperature, before the solution was separated by ultra-centrifugation
at 42,800g for 15min at 4 °C. The pellet containing the activated na-
noparticles was re-suspended and diluted with HEPES buffer (0.025M,
pH 6.4) to a volume of 1.1 mL. To this suspension, 100 µL of the CPP
solutions with varying concentrations of RRH (10, 50 and 75mM), TAT
(2.9, 5.7, and 8.6mM) and bTAT (4.5mM and 6mM) were added. The
mixture was left to incubate overnight at 4 °C and was then separated
by ultra-centrifugation at 42,800g for 15min at 4 °C. The supernatant
was aspirated and kept at 4 °C until HPLC analysis and the nanoparticle
pellet was stored at 4 °C until required with a maximum storage time of
7 days.
2.2.5. Characterization of PLGA and CPP-tagged PLGA nanoparticles
Dynamic light scattering (DLS) was used to measure the Z-average
diameter and PDI of the nanoparticles (Malvern® Nano ZS, Model Zen
3600, Malvern Instruments, Malvern, UK) equipped with a 633 nm laser
and 173° detections optics. The laser Doppler electrophoresis technique
was used to measure zeta potential of the nanoparticles with the same
instrument. All samples were diluted to an appropriate concentration
and measurements of three individual batches were taken in triplicate.
The morphologies of the PLGA and CPP-tagged PLGA nanoparticles
prepared using the bulk nanoprecipitation method and the micro-
fluidics method were investigated using transmission electron micro-
scopy (TEM). First, the carbon film on a 300 mesh copper grid was
made hydrophilic by glow discharge in air (Aebi and Pollard, 1987).
Afterwards, 10 µL of the PLGA nanoparticle suspension was placed on
the grid for 1min and excess suspension was blotted before the grid was
washed twice with ultra-pure water and stained to contrast the spe-
cimen with phosphotungstic acid (1% w/v, pH 6.8). The samples were
viewed on a Phillips CM100 BioTWIN TEM (Philips Electron Optics,
Eindhoven, The Netherlands) and the micrographs were recorded using
a MegaView3 camera (Soft Imaging System, Münster, Germany).
2.2.6. Investigation of binding between CPPs and PLGA
To investigate any interactions between the CPPs and PLGA,
Fourier-transform infrared spectroscopy (FTIR) spectra of PLGA
polymer, CPPs and PLGA-CPP conjugates were recorded with a Varian
3100 FTIR (Varian, Palo Alto, USA) using transmission mode and
compared. The spectra were obtained at wavenumbers between 400
and 4000 cm−1 with 64 scans per sample and a resolution of 4 cm−1.
The PLGA-CPP conjugates were prepared using the zero-length cross-
linking reaction. The PLGA polymer was dissolved in ACN (10mg/mL)
and to a 1mL solution of the polymer 250 μL EDC (1.5 mM in ultra-pure
water) and 250 μL of sulfo-NHS (2mM in ultra-pure water) were added.
The mixture was gently stirred on a magnetic stirring plate for 30min
and then precipitated by adding 3mL of ultra-pure water and separated
by centrifugation at 3220g for 20min at 8 °C (Karve et al., 2011). The
supernatant was removed and the pellet re-suspended in ACN and
200 μL of CPP solutions (50mM RRH, 8.6mM TAT and 4.5 mM bTAT)
were added and incubated while gently stirred at room temperature for
30min. The PLGA-CPP conjugates were precipitated again as described
above and the pellet was dissolved in ACN at a 1:10 ratio (v/v).
The PLGA polymer was dissolved in ACN at a concentration of
10mg/mL and the CPPs were dissolved in 20 μL ultra-pure water and
then diluted with ACN to the intended concentration (50mM RRH,
8.6 mM TAT and 4.5 mM bTAT) before analysis.
2.2.7. Conjugation efficiency of CPPs tagged to PLGA nanoparticles
The conjugation efficiency of the CPPs was obtained indirectly from
the amount of CPPs remaining in the supernatant. The supernatant was
collected after overnight incubation of the activated nanoparticles with
the different concentrations of the three CPPs as described in Section
2.2.4.
CPP concentrations in the supernatant were quantified with vali-
dated RP-HPLC methods using the Agilent™ series 1200 HPLC system
(Agilent Technologies, Santa Clara, USA) with a reverse phase column
(HiChrom ultrasphere 5 ODS, 250×4.6mm, 5 µm particle size, 300 Å
pore size (HiChrom, Theale, UK)) and a UV detector (G1314B) at wa-
velengths between 214 and 220 nm. The aqueous mobile phase con-
tained 0.1% (v/v) TFA in ultra-pure water and the organic mobile phase
contained 0.1% (v/v) TFA in ACN. The CPPs in the supernatant were
eluted by gradient (0–7% over 25min for RRH, 0–13% over 37min for
TAT and 12–22% over 25min for bTAT) at a flow rate of 0.6mL/min.
The CPP concentration was quantified using peak integration and an
individual standard curve was produced for each CPP. The limits of
quantification and the limits of detection are summarized in Table 2.
Eq. (1) was used to calculate the conjugation efficiency of the dif-
ferent CPPs used in the study. The conjugation efficiency was obtained
by calculating the difference between the total concentration of CPPs
added to the nanoparticle suspension and the measured concentration
of CPPs in the supernatant after conjugation.
= ×
−
Conjugation
efficiency (%) 100%Total conc. Measured conc.Total conc.
CPP CPP
CPP (1)
Table 2
The limit of quantification and the limit of detection for the three different
HPLC assays to quantify the concentration of each of the CPPs.
Limit of quantification (LoQ) µg/mL Limit of detection (LoD) µg/mL
RRH 5.4 1.8
TAT 3.1 1.0
bTAT 2.7 0.9
S. Streck, et al. International Journal of Pharmaceutics: X 1 (2019) 100030
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2.2.8. Statistical analysis
All experiments were performed in triplicate and results are pre-
sented as mean ± standard deviation (SD). Statistical analysis for de-
sign of experiments was performed using one-way analysis of variance
(ANOVA) with MODDE GO 12 software. Comparisons between groups
were made by performing a Student’s t test. The reported p-values were
considered statistically significant at p < 0.05.
3. Results and discussion
3.1. Optimal PLGA and stabilizer concentration for the formulation of
PLGA nanoparticles determined by design of experiments
The size of nanoparticles plays a crucial role in cellular uptake and
formulation of PLGA nanoparticles with a size below 200 nm facil-
itating cellular uptake via endocytosis (Sharma et al., 2015). In a design
of experiments study the influence of PLGA concentration, stabilizer
concentration and stirring time on the size and PDI of PLGA nano-
particles was investigated. A response surface plot was used for model
interpretation and represents the combined effect of alterations of the
input factors on the output response (Bairagi et al., 2018; Yadav and
Sawant, 2010). The response surface plot obtained for size of PLGA
nanoparticles prepared using a bulk nanoprecipitation method showed
that a low concentration of PVA (≥ 2%) and a low concentration of
PLGA (< 15mg/mL) was advantageous for the production of PLGA
nanoparticles with a size of approximately 150 nm (Fig. 2A). The sig-
nificant factors influencing the size of PLGA nanoparticles were the
concentration of PLGA polymer, the concentration of PVA and the in-
teraction term PLGA * PVA. Stirring time was found to have no sig-
nificant influence on the size and PDI of PLGA nanoparticles and a
stirring time of 2 h and 15min, equal to the centre point of the design of
experiments, was selected for the preparation of PLGA nanoparticles.
With increasing concentrations of PLGA and PVA, size increased to
approximately 200 nm. This observation was similar to other studies
that reported an increase in nanoparticle size of PLGA nanoparticles
when increased concentrations of PLGA (Sonam et al., 2014; Tefas
et al., 2015) and PVA (Patel et al., 2016; Sonam et al., 2014) were used.
The PDI of the formulated PLGA nanoparticles was highly depen-
dent on the PLGA concentration and was not influenced by the PVA
concentration (Fig. 2B). The response surface plot showed that the PDI
of PLGA nanoparticles formulated using the bulk nanoprecipitation
method was the lowest between 10 and 22mg/mL of the PLGA polymer
and increased towards higher PDI values outside of this PLGA con-
centration range. This is in contrast to literature reporting on increased
PDI with increasing polymer concentration (Patel et al., 2016). The PDI
indeed increased with PLGA polymer concentrations above 20mg/mL,
but also at concentrations below 5mg/mL of the PLGA polymer, which
might be due to the instability of the formed PLGA nanoparticles at the
low polymer concentration and a subsequent nanoparticle aggregation
(Fig. 2B).
The partial least square model of size and PDI for the formulation of
PLGA nanoparticles was analyzed with ANOVA to describe the quality
of the model (Table 3). The values for R2 and Q2 (Table 3) were above
the recommended values from the literature (R2 > 0.75, Q2 > 0.60)
(Mandenius and Brundin, 2008) and provide support that the models of
size and PDI produced with a bulk nanoprecipitation method were able
to fit the data and can be used to predict new data. The p-values for the
regression of the models were<0.05 and lack of fit p-values were ei-
ther above or approximating 0.25, indicating that both models were
significant and statically good at a 95% confidence interval.
The response surface plots for the size and PDI of the experimental
data were used to select the parameters to produce optimized nano-
formulations. The selected optimized parameters from the response
surface plot for further experiments were a PLGA concentration of
10mg/mL and a PVA concentration of 2% (w/v).
3.2. Characterization of PLGA nanoparticles
PLGA nanoparticles prepared using the bulk nanoprecipitation
method had a significantly larger size compared to PLGA nanoparticles
prepared using the microfluidics method (Table 4). PLGA nanoparticles
formulated with both methods were monodisperse, but the PDI of the
PLGA nanoparticles was higher when prepared with the microfluidics
method. Patel et al. (2016) reported that a decrease in PDI was obtained
with an increasing ratio between the aqueous and organic solutions
from 3:1 to 6:1 for the formulation of cromolyn-loaded PLGA using a
bulk nanoprecipitation method. A similar observation was made in the
present study where the bulk nanoprecipitation method with a higher
ratio between the aqueous and organic phase (20:1) yielded nano-
particles with a lower PDI compared to the microfluidics method,
where the ratio between the aqueous and organic phase was 6:1. Using
a higher ratio between the aqueous and organic phase during the pre-
paration of polymeric nanoparticles results in a greater dilution of the
organic polymer solution and the formed nanoparticles are less likely to
aggregate. The higher ratio of aqueous to organic phase in the bulk
nanoprecipitation method did not reduce the size of PLGA
Fig. 2. Response surface plots for the size (nm) (A) and polydispersity index (PDI) (B) of nanoparticles as a function of PLGA and PVA concentration for preparation
of PLGA nanoparticles using the bulk nanoprecipitation method.
Table 3
Summary of results for the statistical analysis of the size and polydispersity
index models for the bulk nanoprecipitation method to produce PLGA nano-
particles.
R2 Q2 Regression p Lack of fit Significant
Size 0.963 0.806 > 0.001 0.442 Yes
Polydispersity index 0.869 0.763 0.006 0.234 Yes
S. Streck, et al. International Journal of Pharmaceutics: X 1 (2019) 100030
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nanoparticles and the formation of nanoparticles> 180 nm might be
due to a polymer concentration above the critical polymer concentra-
tion (Lepeltier et al., 2014). The zeta potential of PLGA nanoparticles
prepared with the two methods were similar (Table 4) and a negative
surface charge below −20mV suggested the presence of negatively
charged carboxyl groups on the surface of the PLGA nanoparticles
(Vasconcelos et al., 2015). The TEM micrographs revealed that PLGA
nanoparticles with a spherical shape were obtained with both pre-
paration methods (Fig. 3A and C).
With both preparation methods, the size of the PLGA nanoparticles
increased with the conjugation of TAT (Table 4), suggesting successful
conjugation of the CPP to the surface of the PLGA nanoparticles
(Vasconcelos et al., 2015). The TAT-tagged PLGA nanoparticles pro-
duced using the microfluidics method were significantly smaller than
TAT-tagged PLGA nanoparticles produced using the bulk nanoprecipi-
tation method (Table 4). Further, the TAT-tagged PLGA nanoparticles
prepared with the bulk nanoprecipitation method showed a size of
200 nm with a high standard deviation indicating a low batch to batch
reproducibility (Table 4). The zeta potential of TAT-tagged PLGA na-
noparticles prepared in this study was between −4 and −6mV
(Table 4). Although there was a shift in zeta potential to become less
negative after conjugation of TAT, the overall negative zeta potential
indicated that negatively charged carboxyl groups of the PLGA polymer
were still present on the surface and that the surface density of TAT was
not sufficient to achieve a positive surface charge (Gullotti and Yeo,
2012). The obtained surface charge of the TAT-tagged PLGA nano-
particles in the present study was within the range of −7 to +3mV
published in the literature for TAT conjugated to PLGA-PEG or PLGA
nanoparticles with a size larger than 200 nm (Gartziandia et al., 2016;
Xu et al., 2013). The conjugation efficiency of TAT conjugated to the
PLGA nanoparticles was not different after production of the nano-
particles using the bulk nanoprecipitation or microfluidics method,
with 55.3 ± 0.7% and 56.3 ± 1.0% conjugation efficiency, respec-
tively (Table 4). However, since the PLGA nanoparticles prepared with
the microfluidics method had a smaller size, more surface area of the
nanoparticles might be covered with TAT to mask the negative charges
of the carboxyl group of PLGA resulting in a slightly less negative zeta
potential (Table 4). The morphology of the CPP-tagged PLGA nano-
particles did not change with the conjugation of TAT to PLGA nano-
particles prepared using the bulk nanoprecipitation or microfluidics
method (Fig. 3B and E). Similarly, the conjugation of RRH and bTAT to
PLGA nanoparticles prepared using the microfluidics method did not
influence the morphology of the nanoparticles (Fig. 3D and F). The
microfluidics method was selected for further investigations of the
utility of this method for producing CPP-tagged PLGA nanoparticles due
to the smaller nanoparticle size with better reproducibility.
3.3. Investigation of binding between CPPs and PLGA polymer
FTIR was used for the physicochemical characterization of the PLGA
polymer, the three different CPPs and PLGA-CPP conjugates. The FTIR
spectrum of the PLGA polymer alone showed the characteristic C]O
stretch of the carboxyl group at 1749 cm−1 and C–O ester stretches
between 1167 and 1086 cm−1 (Fig. 4). The individual CPPs showed
bands related to the amide I and II bond vibration at 1667–1659 and
1541–1560 cm−1, respectively (Fig. 4). The amide bond I and II vi-
brations were associated with the C]O stretching and N–H bending of
the amide bonds between the individual amino acids of the CPPs (Haris
and Severcan, 1999). In addition, C–O ester stretch vibrations from the
C-terminal amino acid of the CPPs were observed between 1202 and
1130 cm−1 (Fig. 4).
PLGA nanoparticles tagged with CPPs were analyzed using FTIR,
however the FTIR spectrum showed broad and weak FTIR bands, which
made assignment of wavenumbers difficult. Therefore, PLGA-CPP
conjugates prepared by covalently attaching CPPs to the PLGA polymer
were used to identify any interactions between the PLGA polymer and
the CPPs. The carboxyl group of the PLGA polymer and the primary
amine of the CPPs were utilized to form a covalent bond using a zero-
length crosslinking reaction (Hermanson, 2013). Conjugation between
the CPPs and PLGA polymer was confirmed with the observation of an
amide I bond vibration in the CPP-PLGA conjugates at approximately
1635 cm−1. The shift of the amide I bond vibration to a lower wave-
length in comparison to the amide I bond vibration in RRH, TAT and
bTAT (1667–1659 cm−1) provided evidence of the successful formation
of a covalent bond between these two components (Fig. 4). The FTIR
spectra of the PLGA-CPP conjugates also showed a C]O stretch at
1763 cm−1 for the carboxyl group of the PLGA polymer indicating that
there were unconjugated carboxyl groups present.
3.4. Characteristics of CPP-tagged PLGA nanoparticles depends on the CPP
architecture
The influence of the CPP architecture on the characteristics of CPP-
tagged PLGA nanoparticles was investigated by using a zero-length
crosslinking reaction to conjugate CPPs to the surface of PLGA nano-
particles produced using microfluidics. PLGA nanoparticles had an
average size of 150 nm and a zeta potential of−19mV (Fig. 5A and B).
With conjugation of the three different CPPs the size of the nano-
particles increased, but the increase in size was independent of the
concentration of CPP (Fig. 5A). The slight increase in size of the CPP-
tagged PLGA nanoparticles could be attributed to the presence of CPPs.
Further, nanoparticles may increase in size due to swelling caused by
the more hydrophilic surface of the CPP-tagged PLGA nanoparticles
compared to PLGA nanoparticles (Feiner-Gracia et al., 2018).
The influence of different CPP concentrations on the physico-
chemical characteristics of CPP-tagged PLGA nanoparticles was eval-
uated to design nanoformulations with a diameter below 200 nm and a
neutral zeta potential to be suitable for future investigations as oral
drug delivery system. Studies have shown PLGA nanoparticles with a
size below 200 nm were taken up by Caco-2 cells to a higher extent
compared to larger nanoparticles and that the surface charge of nano-
formulations influences the electrostatic interactions with the nega-
tively charged cell membrane (Danhier et al., 2012; Gaumet et al.,
2009). The zeta potential of RRH-tagged PLGA nanoparticles shifted
from−24 to−12mV with increasing concentrations of RRH (Fig. 5B).
The conjugation of TAT resulted in the formation of slightly negative
Table 4
Characterization of PLGA and TAT-tagged PLGA nanoparticles prepared with the optimized parameters for the bulk nanoprecipitation method and with the mi-
crofluidics method. Data are means ± SD (n=3 independent batches). *p-value<0.05 in comparison to the respective bulk method.
Size ± SD (nm) PDI ± SD Zeta potential ± SD (mV) Conjugation efficiency (%)
Unmodified PLGA nanoparticles
Bulk 184.0 ± 3.9 0.110 ± 0.007 −23.0 ± 0.8 N/A
Microfluidics 151.2 ± 1.2* 0.149 ± 0.014 −22.2 ± 0.5 N/A
TAT-tagged PLGA nanoparticles
Bulk 201.9 ± 12.5 0.136 ± 0.057 −6.0 ± 3.4 55.3 ± 0.7
Microfluidics 172.4 ± 2.6* 0.164 ± 0.014 −4.3 ± 0.8 56.3 ± 1.0
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TAT-tagged PLGA nanoparticles with a surface charge of −4mV
(Fig. 5B). After conjugation of bTAT to the PLGA nanoparticles the zeta
potential was slightly positive (+3mV, Fig. 5B). The change in zeta
potential can be explained by the architecture of the CPPs. The CPPs are
characterized by a short, long linear and branched architecture (Fig. 1).
The number of positive charges in the peptide sequence is increased
with a longer and more complex architecture. RRH contains 2 positive
charges in the peptide sequence, whereas TAT and bTAT contain 8 and
12 positive charges, respectively. The increase in positive charges from
RRH > TAT > bTAT resulted in positively charged bTAT-tagged
PLGA nanoparticles after the post-microfluidics conjugation approach.
According to the PDI values all CPP-tagged PLGA nanoparticles showed
Fig. 3. TEM micrographs of unmodified PLGA (A) and TAT-tagged PLGA nanoparticles (B) prepared using a bulk nanoprecipitation method and unmodified PLGA
(C), RRH- (D), TAT- (E) and bTAT-tagged PLGA nanoparticles (F) prepared using a microfluidics method.
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a monodisperse size distribution (Fig. 5A) and no aggregation was ob-
served. This is in contrast to the literature, where highly negatively or
positively charged nanoparticles with a zeta potential below −30 and
above +30mV are believed to be more stable because of stronger re-
pulsion forces than between neutral charged nanoparticles with a zeta
potential between −10 and +10mV (Sonam et al., 2014; Tefas et al.,
2015; Vasconcelos et al., 2015).
3.5. Conjugation efficiency of CPPs with different architectures on PLGA
nanoparticles
The amount of CPPs binding to the surface of PLGA nanoparticles
depends on the number of available carboxyl groups and the orientation
of the CPP. The number of binding sites on a single PLGA nanoparticle
with a size of 155 nm was estimated to be 16,000. For this calculation
the ratio between the lactic and glycolic acid groups (50:50) and their
Connolly surface area was considered (Connolly, 1983). The three dif-
ferent CPPs have multiple primary amines that are likely to act as a
binding site depending on their position in the CPP sequence (Fig. 1).
An estimate of the amount of CPPs covalently attached to the surface
available carboxyl groups of the PLGA nanoparticles was quantified by
calculating the conjugation efficiency. The conjugation efficiency for
RRH, TAT and bTAT depended on the concentration of the CPPs added
(Table 5). The amount of RRH conjugated to the PLGA nanoparticles
increased by 12-fold when the concentration of RRH was increased
from 10 to 50mM. A further increase in the RRH concentration to
75mM resulted in a slight decrease in conjugation efficiency, sug-
gesting that at 50mM there was a saturation of the surface available
carboxyl groups on the PLGA nanoparticles that can react with the
primary amines in RRH. The concentration of TAT conjugated to PLGA
nanoparticles increased in a linear manner with increasing concentra-
tions of the CPP. The bTAT-tagged PLGA nanoparticles showed a si-
milar concentration of bTAT conjugated to the surface of the PLGA
nanoparticles as TAT (Table 5). These results can be related to the
structure of the CPPs. The short CPP RRH showed the highest con-
centration of CPP on the surface, which is related to the amount of RRH
that was added and the shorter amino acid sequence in comparison to
the other two CPPs. The concentrations of TAT and bTAT conjugated to
the PLGA nanoparticles were similar and the amount of CPP that can be
conjugated might be limited because of the more complex and branched
architecture of the CPPs, which induced steric hindrance between in-
dividual CPP molecules. With the conjugation of TAT and bTAT to the
surface of PLGA nanoparticles, it is possible that not all available
binding sites would be used due to the orientation of the CPPs. TAT has
primary amines along the amino acid sequence and can, therefore, bind
Fig. 4. FTIR spectra of PLGA polymer, the individual cell-penetrating peptides
(RRH, TAT, bTAT) and PLGA-CPP conjugates.
Fig. 5. Size, PDI (A) and zeta potential (B) of PLGA nanoparticles and CPP-
tagged PLGA nanoparticles with different concentrations of CPPs prepared
using the post-microfluidics conjugation approach. Size is displayed as circles
and triangles represent PDI. Data are means ± SD (n=3 independent bat-
ches). *p-value< 0.05 for the comparison of CPP-tagged PLGA nanoparticles
with PLGA nanoparticles, ns= not significant.
Table 5
Conjugation efficiencies and the equivalent concentration of the CPPs tagged to
PLGA nanoparticles (NPs) using different concentrations of CPPs prepared with
a post-microfluidics conjugation approach. Data are means ± SD (n=3 in-
dependent batches). *p-value< 0.05 in comparison to the conjugation effi-
ciency of 8.6mM TAT.
CPP concentration
(mM)
Conjugation efficiency
(%) ± SD
CPP concentration
(µM) ± SD
RRH-tagged PLGA NPs
10 32.4 ± 0.8 0.25 ± 0.03
50 74.4 ± 4.5 3.10 ± 0.19
75 58.5 ± 6.0 3.66 ± 0.37
TAT-tagged PLGA NPs
2.9 57.6 ± 0.5 0.150 ± 0.001
5.7 56.3 ± 1.0 0.29 ± 0.01
8.6 55.5 ± 0.8 0.43 ± 0.01
bTAT-tagged PLGA NPs
4.5 79.8 ± 0.3* 0.327 ± 0.001
6.0 45.4 ± 0.7 0.248 ± 0.004
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in an orientation perpendicular to the nanoparticle surface or with a
more tangential orientation in relation to the nanoparticle surface. A
tangential orientation of the CPP may cover other binding sites on the
surface of the PLGA nanoparticles since the tangential orientation
covers more surface area. The same applies to the bTAT, which has
primary amino acids in the long linear backbone and the short bran-
ches.
4. Conclusion
The design of experiments study of the bulk nanoprecipitation
method showed that the PLGA polymer concentration and the surfac-
tant concentration influenced the size and PDI of PLGA nanoparticles.
The optimized concentrations of the PLGA polymer and surfactant were
used in the microfluidics method and the size of PLGA nanoparticles
was reduced compared to the size of PLGA nanoparticles prepared with
the bulk nanoprecipitation method. The successful functionalization of
CPPs to the PLGA polymer was shown by the formation of amide bonds.
The CPP architecture determined the physicochemical characteristics
and especially the zeta potential of the CPP-tagged PLGA nanoparticles.
The surface charge was tuned from negatively charged RRH- and TAT-
tagged PLGA nanoparticles to slightly positively charged bTAT-tagged
PLGA nanoparticles with the introduction of a branched CPP archi-
tecture. The CPP-tagged PLGA nanoparticles with tuned surface prop-
erties have the potential to be an effective drug delivery system in-
tended for oral administration of drugs.
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